Abstract
Background:
Surgical parathyroidectomy (PTX) is necessary for patients with severe and progressive secondary hyperparathyroidism (SHPT) refractory to medical treatment. Recurrence of SHPT after PTX is a serious clinical problem. Both supernumerary mediastinal parathyroid gland and parathyromatosis are the rare causes of recurrent renal SHPT. We report a rare case of recurrent renal SHPT due to supernumerary mediastinal parathyroid gland and parathyromatosis.
Case presentation:
A 53-year-old man underwent total parathyroidectomy with autotransplantation due to the drug-refractory SHPT 17 years ago. In the last 11 months, the patient experienced symptoms including bone pain and skin itch, and the serum intact parathyroid hormone (iPTH) level elevated to 1,587 pg/ml. Ultrasound detected two hypoechoic lesions located at the dorsal area of right lobe of the thyroid gland, and both lesions presented as characteristics of hyperparathyroidism in contrast-enhanced ultrasound. 99mTc-MIBI/SPECT detected a nodule in the mediastinum. A reoperation involved a cervicotomy for excising parathyromatosis lesions and the surrounding tissue and a thoracoscopic surgery for resecting a mediastinal parathyroid gland. According to a histological examination, two lesions behind the right thyroid lobe and one lesion in the central region had been defined as parathyromatosis. A nodule in the mediastinum was consistent with hyperplastic parathyroid. The patient remained well for 10 months with alleviated symptoms and stabilized iPTH levels in the range of 123–201 pg/ml.
Conclusion:
Although rare, recurrent SHPT may be caused by a coexistence of both supernumerary parathyroid glands and parathyromatosis, which should receive more attention. The combination of imaging modalities is important for reoperative locations of parathyroid lesions. To successfully treat parathyromatosis, all the lesions and the surrounding tissue must be excised. Thoracoscopic surgery is a reliable and safe approach for the resection of ectopic mediastinal parathyroid glands.
Introduction
Secondary hyperparathyroidism (SHPT) is a common complication of end-stage renal disease (ESRD) (1). SHPT can causes bone pain and itching (2, 3), which contribute to the poor quality of life in dialysis patients. Moreover, prolonged SHPT is significantly associated with high incidences of cardiovascular events and all-cause mortality (4, 5). Surgical parathyroidectomy (PTX) is necessary for patients with severe and progressive SHPT refractory to medical treatment (6). A mountain of evidence identified that PTX can alleviate clinical symptoms, improve the quality of life, and reduce the risk of all-cause and cardiovascular mortality in patients with severe and progressive SHPT (7–9). Although PTX is generally a successful treatment for SHPT patients subjected to surgery, a significant proportion develop recurrent SHPT after PTX, ranging between 5% and 38%. Recurrent SHPT is mainly caused by the hyperplastic autografted tissue, remnant parathyroid tissues left in the neck, and the presence of ectopic and/or supernumerary parathyroid glands (SPGs) (10–14). SPGs are found commonly in the thymus, and the presence of SPGs in the mediastinum is rare in patients with SHPT (11, 12, 14). Moreover, parathyromatosis is a very rare cause of recurrent SHPT, which is characterized by hyperfunctional parathyroid foci in the parathyroid autotransplant sites and the primary surgery site (15, 16). There is a lack of discussion on the optimal management for recurrent SHPT, caused by ectopic mediastinal parathyroid glands or parathyromatosis, in the literature. Herein, we present an unusual case caused by mediastinal supernumerary parathyroid glands and parathyromatosis.
Case presentation
A 53-year-old male was admitted to our hospital in November 2021 with progressive aggravation of recurrent bone pain and skin itch for 11 months. He had a history of chronic glomerulonephritis for 27 years and hemodialysis for 25 years. Seventeen years ago, he was diagnosed with SHPT due to complaints of bone pain, skin itch, and a significant increase in serum intact parathyroid hormone (iPTH) (>1,000 pg/ml), and a surgical parathyroidectomy was required. During the initial operation, four glands were removed and then confirmed as hyperplasia histopathologically, and about 30 mg tissues from the smallest one among the resected glands were implanted into right forearm at the same time. The serum iPTH decreased to 85 pg/ml on postoperative day 1, which further indicated a successful surgery had been performed. After the initial operation, the patient did not receive any drug, and serum iPTH levels were stabilized in the range of 80.5–150 pg/ml during the 3-year follow-up. The serum iPTH levels increased to 400–500 pg/ml 14 years ago, and the cause of elevated iPTH level has been considered as hyperplastic autografts in other institutions. During this period, he did not receive any imaging examinations. Then, the patient started to receive active vitamin D supplements of Rocaltrol treatment, and the iPTH levels were stabilized in the 150–300 pg/ml range until December 2020.
On December 2020, the patient visited our institution due to the return of symptoms including bone pain and skin itch. Routine laboratory tests showed that serum iPTH increased to 1,587 pg/ml, and calcium and phosphate levels were 2.38 mmol/L and 2.79 mmol/L, respectively. Recurrent renal SHPT was diagnosed, and the further examinations were recommended to locate the hyperfunctional parathyroid tissues, but the patient refused and medication was adopted. Unfortunately, therapies such as low phosphorus diet, phosphorus binders, calcitriol, calcium supplements, and vitamin D were ineffective.
On November 2021, the patient visited our institution for evaluation again because of insupportable symptoms. Laboratory tests revealed that the serum iPTH, calcium, and phosphate were 1,100 pg/ml, 2.26 mmol/L, and 2.85 mmol/L, respectively. In the dorsal area of right thyroid lobe, ultrasound (US) detected two hypoechoic formations with volumes of 0.55 cm × 0.45 cm and 0.55 cm × 0.35 cm (Figure 1A), which presented as a vascularization pattern of parathyroid lesions (fast-in, slow-out, and higher-enhancement with long enhancement time) when examined by using contrast-enhanced ultrasound (CEUS) (Figure 1B). 99mTc-sestamibi (99mTc-MIBI)/single photon emission computed tomography (SPECT) did not find any tracer accumulation in the sites of neck and autograft but revealed a nodule (1.5 cm × 1.0 cm) with tracer uptake in the mediastinum (Figure 1C). Reoperation involved a cervicotomy and a thoracoscopic surgery was performed on 24 November 2021. Cervicotomy was performed to remove the suspected recurrent parathyroid tissue and the surrounding tissue around the right thyroid lobe (Figure 2A1–3). Besides two lesions of the neck detected by US and CEUS, another lesion was found in the central compartment of the neck during the reoperation (Figure 2A3), which made us believe that the hyperplastic parathyroid tissues at this region mainly resulted from a secondary implantation into the surrounding tissues of the damaged parathyroid gland during the initial operation. Therefore, the clearance of the central neck compartment also was performed (Figure 2C). A thoracoscopic surgery was performed to remove the hypertrophic mediastinal parathyroid gland (Figure 2A4). During surgery, an adequate PTH drop was achieved (246 pg/ml). Therefore, we did not perform a further exploration to make sure whether there are functional parathyroid tissues in the autografted site. According to the histological study, three lesions of parathyroid tissues at the site of primary surgery are represented by diffuse-nodular hyperplasia from dark main cells and nodular hyperplasia shown in fibroadipose tissues, and these lesions do not have their own capsule and suture material surrounded by nodular hyperplasia (Figure 2B1–3). Pathologic analysis of the resected mediastinal parathyroid gland showed nodular hyperplasia of parathyroid tissue, which was well differentiated (Figure 2B4). On the first day after operation, the iPTH level in a blood specimen obtained from the right arm was 185 pg/ml, whereas it was 123 pg/ml from the left arm. On the fifth day after operation, 99mTc-MIBI/SPECT was performed, and no suspected parathyroid tissues were detected in the neck or the mediastinum (Figures 3A,C). Interestingly, a weak focal tracer accumulation had presented in the autograft site (Figure 3B), indicating the existence of functional parathyroid tissues in the autograft site. During 10 months of follow-up, his itching and bone pain significantly improved, and he had appropriate calcium (2.09–2.27 mmol/L) and iPTH (108–195 pg/ml, blood specimen from the left arm) levels under regular hemodialysis (Table 1).
Figure 1
Figure 2
Figure 3
Table 1
| Background | Presentation | Evaluation | Surgical findings | Treatment | Outcome |
|---|---|---|---|---|---|
| 53-year-old male, TPTX + AT due to the SHPT 17 years ago | Bone pain, skin itch, and elevated level of iPTH | Blood test, US, CEUS, and 99mTc-MIBI/SPECT | Parathyroid gland in central compartment of the neck and mediastinum | Excision of parathyroid glands in the neck and mediastinum | Hospital discharge a week after surgery |
Summary of the case.
TPTX + AT, total parathyroidectomy with autotransplantation; SHPT, secondary hyperparathyroidism; iPTH, intact parathyroid hormone; US, ultrasound; CEUS, contrast-enhanced ultrasound.
Discussion
Recurrent SHPT is an uncommon yet challenging clinical problem (10, 17–22). Great efforts had been made to reduce the incidence of recurrent SHPT over the past decade. For example, previous studies had been performed to evaluate the recurrence of all types of surgical procedures (10, 17–20), and the results showed that total parathyroidectomy (TPTX) is superior with regard to the prevention of recurrence. However, TPTX can result in intractable postoperative hypocalcemia, a common complication that can increase mortality and hospitalization, and implementing long-term oral calcium and vitamin D is need after surgery (23). Considering the life-threatening sequelae, TPTX alone is not frequently performed for patients. Total parathyroidectomy with autotransplantation (TPTX + AT) has the advantage of avoiding long-term hypocalcemia but has an increased risk of recurrent SHPT induced by the autotransplanted parathyroid tissues (19, 22, 24).
Recurrent SHPT is one of the significant reasons for the dependence of transplant recipients on parathyroidectomy. Over time, the recurrence rate gradually increases and can reach up to 30% (24). First, this may be related to the pathological type of the transplanted parathyroid gland, as early parathyroid glands exhibit diffuse polyclonal proliferation, and late parathyroid glands may develop into adenomatous tissues due to certain genetic abnormalities and undergo monoclonal expansion (25). Second, in chronic kidney disease (CKD) patients who require dialysis, various physiological stimuli persist, including hyperphosphatemia, hypocalcemia, and lack of calcitriol. Under these circumstances, the parathyroid gland is more susceptible to hypertrophy, and both free and settled parathyroid cells eventually develop into glands with strong PTH secretion capacity (26). Additionally, the use of certain drugs may also promote the recurrence of secondary hyperparathyroidism (27).
SPGs have been demonstrated as a major cause of persistent or recurrent SHPT (11–13). Previous studies reported that SPGs had been found in 15%–39% of reoperative patients (12, 28). SPGs may result from separation of the parathyroid anlage during embryologic migration. SPGs usually present as parathyroid foci that cannot be detected by the recent imaging modalities and easily missed during the initial surgery (13, 29). These missed parathyroid foci, under ongoing stimulus of renal failure, would grow slowly and develop into the obvious glands and then the recurrence appears. In this case, the patient did have a long period of good recovery after the initial surgery, and an obvious gland had been found in the mediastinum that was determined as SPG during the reoperation. SPGs are found commonly in the thymus region, and a routine cervical thymectomy is recommended during the surgical treatment of patients with SHPT (11, 12, 14). Uno et al., for instance, in a retrospective study of 902 patients submitted to PTX and cervical thymectomy due to SHPT, found SPGs presented in 140 (15.5%) patients, located in the thymus region in 129 patients (92.1% of the number of patients with SPGs) (14). Importantly, previous studies demonstrated that the risk of recurrent SHPT in patients who underwent PTX and thymectomy is much lower than that in patients without thymectomy (12). Moreover, SPGs are also found to be located in the retroesophageal groove, carotid sheath, and mediastinum. It needs to be noticed that mediastinal localization of SPGs was initially low but its presence is not infrequent in the reoperative cases (12, 13). During reoperations, the incidence of mediastinal SPGs was estimated to be present in about 3.5%–30% of patients (12, 30). SPG excision here may necessitate sternotomy or thoracoscopy (31–34). In this case, we performed a thoracoscopic surgery to remove the mediastinal parathyroid gland. In accordance with previous studies (33, 34), we found the thoracoscopic approach for mediastinal SPGs to be feasible and safe.
Parathyromatosis is a rare cause of recurrent SHPT (15). There are two theories to explain the pathogenesis of parathyromatosis. The first (type 1) defines as preexisting parathyroid rests of embryological origin that undergo hyperplasia under the influence of physiological stimuli. The second (type 2), also known as the main cause of parathyromatosis, is a consequence of implantation into the surrounding tissues of the damaged parathyroid gland during the primary operation. In this case, one of the causes of recurrent SHPT was considered to be type 2 parathyromatosis because small and numerous nodules had been found in the primary surgical site and these nodules are surrounded by dense fibrous tissues. Optimal treatment for SHPT can be achieved by surgical resection, whereas in parathyromatosis, it is difficult to find and remove all the lesions intraoperatively hence requiring multiple surgeries. A previous literature study reported that only 4 of 10 patients were successfully diagnosed with parathyromatosis preoperatively, and the failure reoperation has been found in 6 of 10 patients with parathyromatosis (16). US may be more effective than sestamibi scan in finding the parathyromatosis. In this case, 99mTc-MIBI/SPECT failed to find the suspected parathyroid tissues in the neck, but US detected two lesions with a small volume located at the primary site. Previous studies showed that the suspected parathyroid lesions could be identified accurately by using CEUS (35). Indeed, in this case, two lesions, detected by US, presented with a vascularization pattern of parathyroid tissues, which can help diagnose parathyromatosis and prepare a surgery plan. According to our clinical observation, parathyromatosis usually presents as multiple and small-sized foci with surrounding tissue, and these foci would distribute widely in the primary surgery site. Treatment is the surgical removal of all foci. However, berry picking surgery would be a failure for complete excision; thus, an extensive surgery is required with resection of multiple parathyromatosis foci and clearance of the central neck compartment (36). In this case, the extensive surgery was performed, and no recurrence was present on the postoperative 10 months.
Even though TPTX + AT increases the risk of recurrence, it is still widely performed for SHPT patients subjected to surgery because the recurrent site can be easy to identify and remove them under local anesthesia (24). Several researchers thought that selection of the appropriate autograft tissue, the smallest parathyroid gland tissues without adenomatous hyperplasia in initial surgery, would be helpful for avoiding the recurrent SHPT (37). The choice between TPTX with or without AT remains controversial. Li et al. conducted a meta-analysis of 10 cohort studies and 1 randomized controlled trial involving 1,108 patients to compare the two surgical methods. The study found no significant differences in surgical complications, all-cause mortality, persistent hyperparathyroidism, or symptom improvement between the two methods. However, TPTX reduced the risk of recurrence and the need for a second surgery due to recurrence or persistent hyperparathyroidism (38). Liu et al. also conducted a meta-analysis and found that compared to TPTX + AT, the TPTX group had a lower recurrence rate (OR = 0.2, 95%CI: 0.11–0.38, P < 0.01), with no significant differences in complications (39). Hou et al. conducted a network meta-analysis of 26 studies including 5,063 patients and concluded that TPTX + AT was the most effective and least harmful surgical treatment for low calcium and recurrence rate (40). Li et al. compared 62 patients who underwent TPTX with 42 patients who underwent TPTX with forearm autotransplantation (FAT) and found that TPTX + FAT patients had significantly improved postoperative quality of life and lower recurrence rates compared to TPTX patients (41). In general, there is no single best surgical option, only a more suitable one. For patients who need to avoid a second surgery, including those with thyroid disease, multiple neck surgeries, known recurrent laryngeal nerve injury, and general anesthesia intolerance, TPTX + AT is preferred. For patients with longer life expectancy or those who are unlikely to receive kidney transplantation, TPTX has advantages in preventing recurrent refractory secondary hyperparathyroidism (42). In this case, the autograft tissue was chosen from the smallest one among the four resected glands in the initial surgery, and the recurrence of this case is not definitely caused by hyperplasia of the autograft tissues.
While PTX is a highly effective therapeutic option for SHPT, the issue of recurrence remains. Thus, it is of utmost importance to focus on strategies to decrease the incidence of recurrent SHPT after initial surgery. Currently, a consensus on the diagnostic and therapeutic guidelines for initial surgery has yet to be reached. Nevertheless, based on current experience, these guidelines should entail preoperative radiologic imaging, iPTH monitoring, necessary exploration, and possible tissue clearance. Previous studies showed that preoperative localization procedures are useful for complete resection (11, 43–48). Ultrasonography (USG), computed tomography (CT), and 99mTc-sestamibi (99mTC-MIBI) scans are often performed to localize PTGs. Each technique has its own advantages and disadvantages in terms of sensitivity and accuracy. The combinations of various imaging modalities are encouraged to improve the accuracy of preoperative positioning, especially for SPGs and ectopic glands and the glands in the patients with recurrent SHPT (11, 29, 44, 46, 47). In this case, a functional gland in the mediastinum had been detected only by using 99mTC-MIBI/SPECT, and parathyromatosis foci had been found by means of CEUS. Moreover, intraoperative iPTH monitoring, an important tool, is widely used for preventing inadequate surgery in PTX (49, 50). Hiramitsu et al. reported that a 70% intraoperative iPTH drop from baseline 10 min after PTX is appropriate to determine sufficient PTG removal (49). If <70% intraoperative iPTH drop was observed, it is recommended to perform exploration and purging parathyroidectomy (PPTX). This involves a comprehensive resection of cervical fibro-fatty tissues, including the thymus tongue, that are enclosed by the thyroid cartilage, bilateral carotid sheath, and innominate artery (51).
In conclusion, postoperative recurrence of SHPT caused by SPGs and parathyromatosis should receive more attention. Multiple imaging modalities are valuable for precise preoperative localization of suspected parathyroid tissues and may help with subsequent treatment. An extensive surgery needs to be performed for patients with parathyromatosis that is located at the primary surgery site. Thoracoscopic surgery is a feasible and safe technique in the management of mediastinal parathyroid gland.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Ethics statement
This case was approved by the research ethics committee of our institution [No. Y (2022)202]. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
CH, LL, and YT designed the research and wrote the paper. LL and GC performed the surgery. JC provided the data of US and CEUS. YT and WZ revised the paper. WZ and CW collected clinical data. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by the Natural Science Foundation of Liaoning Province (Nos. 20180551256 and 2022-YGJC-11).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
HedgemanELipworthLLoweKSaranRDoTFryzekJ. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. (2015) 2015:184321. 10.1155/2015/184321
2.
Cohen-SolalMFunck-BrentanoTUrena TorresP. Bone fragility in patients with chronic kidney disease. Endocr Connect. (2020) 9(4):R93–101. 10.1530/EC-20-0039
3.
KimDPollockC. Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J. (2021) 14(Suppl 3):i1–7. 10.1093/ckj/sfab142
4.
BozicMDiaz-TocadosJMBermudez-LopezMFornéCMartinezCFernandezEet alIndependent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant. (2022) 37(4):663–72. 10.1093/ndt/gfab184
5.
OgataHKumasawaJFukumaSMizobuchiMKinugasaEFukagawaMet alThe cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study. Clin Exp Nephrol. (2017) 21(5):797–806. 10.1007/s10157-017-1380-2
6.
SteinlGKKuoJH. Surgical management of secondary hyperparathyroidism. Kidney Int Rep. (2021) 6(2):254–64. 10.1016/j.ekir.2020.11.023
7.
FilhoWAvan der PlasWYBresciaMDGNascimentoCPJr.GoldensteinPTNetoLMMet alQuality of life after surgery in secondary hyperparathyroidism, comparing subtotal parathyroidectomy with total parathyroidectomy with immediate parathyroid autograft: prospective randomized trial. Surgery. (2018) 164(5):978–85. 10.1016/j.surg.2018.06.032
8.
Costa-HongVJorgettiVGowdakLHMoysesRMKriegerEMDe LimaJJ. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery. (2007) 142(5):699–703. 10.1016/j.surg.2007.06.015
9.
ChenLWangKYuSLaiLZhangXYuanJet alLong-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Ren Fail. (2016) 38(7):1050–8. 10.1080/0886022X.2016.1184924
10.
RichardsMLWormuthJBingenerJSirinekK. Parathyroidectomy in secondary hyperparathyroidism: is there an optimal operative management?Surgery. (2006) 139(2):174–80. 10.1016/j.surg.2005.08.036
11.
AndradeJSMangussi-GomesJPRochaLAOheMNRosanoMdas NevesMCet alLocalization of ectopic and supernumerary parathyroid glands in patients with secondary and tertiary hyperparathyroidism: surgical description and correlation with preoperative ultrasonography and Tc99m-sestamibi scintigraphy. Braz J Otorhinolaryngol. (2014) 80(1):29–34. 10.5935/1808-8694.20140008
12.
PattouFNPellissierLCNoelCWambergueFHugloDGProyeCA. Supernumerary parathyroid glands: frequency and surgical significance in treatment of renal hyperparathyroidism. World J Surg. (2000) 24(11):1330–4. 10.1007/s002680010220
13.
NumanoMTominagaYUchidaKOriharaATanakaYTakagiH. Surgical significance of supernumerary parathyroid glands in renal hyperparathyroidism. World J Surg. (1998) 22(10):1098–102, discussion 1103. 10.1007/s002689900524
14.
UnoNTominagaYMatsuokaSTsuzukiTShimabukuroSSatoTet alIncidence of parathyroid glands located in thymus in patients with renal hyperparathyroidism. World J Surg. (2008) 32(11):2516–9. 10.1007/s00268-008-9739-x
15.
HageMPSaltiIEl-Hajj FuleihanG. Parathyromatosis: a rare yet problematic etiology of recurrent and persistent hyperparathyroidism. Metab Clin Exp. (2012) 61(6):762–75. 10.1016/j.metabol.2011.11.001
16.
MatsuokaSTominagaYSatoTUnoNGotoNKatayamaAet alRecurrent renal hyperparathyroidism caused by parathyromatosis. World J Surg. (2007) 31(2):299–305. 10.1007/s00268-006-0391-z
17.
RothmundMWagnerPKScharkC. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg. (1991) 15(6):745–50. 10.1007/BF01665309
18.
GasparriGCamandonaMAbbonaGCPapottiMJeantetARadiceEet alSecondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Surg. (2001) 233(1):65–9. 10.1097/00000658-200101000-00011
19.
KievitAJTinnemansJGIduMMGroothoffJWSurachnoSAronsonDC. Outcome of total parathyroidectomy and autotransplantation as treatment of secondary and tertiary hyperparathyroidism in children and adults. World J Surg. (2010) 34(5):993–1000. 10.1007/s00268-010-0446-z
20.
SchlosserKBartschDKDienerMKSeilerCMBrucknerTNiesCet alTotal parathyroidectomy with routine thymectomy and autotransplantation versus total parathyroidectomy alone for secondary hyperparathyroidism: results of a nonconfirmatory multicenter prospective randomized controlled pilot trial. Ann Surg. (2016) 264(5):745–53. 10.1097/SLA.0000000000001875
21.
AbruzzoAGiovialeMCDamianoGPalumboVDBuscemiSLo MonteGet alReoperation for persistent or recurrent secondary hyperparathyroidism. Acta Biomed. (2017) 88(3):325–8. 10.23750/abm.v88i3.4722
22.
SteffenLMoffaGMullerPCOertliD. Secondary hyperparathyroidism: recurrence after total parathyroidectomy with autotransplantation. Swiss Med Wkly. (2019) 149:w20160. 10.4414/smw.2019.20160
23.
IshaniALiuJWetmoreJBLoweKADoTBradburyBDet alClinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. (2015) 10(1):90–7. 10.2215/CJN.03520414
24.
TominagaYUchidaKHabaTKatayamaASatoTHibiYet alMore than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis. (2001) 38(4 Suppl 1):S168–171. 10.1053/ajkd.2001.27432
25.
CunninghamJLocatelliFRodriguezM. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. (2011) 6:913–21. 10.2215/CJN.06040710
26.
NakajimaKUminoKAzumaYKosakaSTakanoKObaraTet alStimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged period. J Bone Min Metab. (2009) 27(2):224–33. 10.1007/s00774-008-0032-8
27.
WuYHanWLiPHuXZhangY. Impact of dexmedetomidine on secondary hyperparathyroidism recurrence in uremic patients who received parathyroidectomy with auto-transplantation: a retrospective propensity-matched study. Am J Transl Res. (2022) 14(9):6659–68. PMID: 36247273
28.
StrackeSKellerFSteinbachGHenne-BrunsDWuerlP. Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism. Nephron Clin Pract. (2009) 111(2):c102–9. 10.1159/000191200
29.
HiramitsuTTomosugiTOkadaMFutamuraKTsujitaMGotoNet alPre-operative localisation of the parathyroid glands in secondary hyperparathyroidism: a retrospective cohort study. Sci Rep. (2019) 9(1):14634. 10.1038/s41598-019-51265-y
30.
NilubolNBeyerTPrinzRASolorzanoCC. Mediastinal hyperfunctioning parathyroids: incidence, evolving treatment, and outcome. Am J Surg. (2007) 194(1):53–6. 10.1016/j.amjsurg.2006.11.019
31.
RussellCFEdisAJScholzDASheedyPFvan HeerdenJA. Mediastinal parathyroid tumors: experience with 38 tumors requiring mediastinotomy for removal. Ann Surg. (1981) 193(6):805–9. 10.1097/00000658-198106000-00016
32.
CupistiKDotzenrathCSimonDRoherHDGoretzkiPE. Therapy of suspected intrathoracic parathyroid adenomas. Experiences using open transthoracic approach and video-assisted thoracoscopic surgery. Langenbecks Arch Surg. (2002) 386(7):488–93. 10.1007/s00423-001-0254-x
33.
LuHIChouFFChiSYHuangSC. Thoracoscopic removal of hypertrophic mediastinal parathyroid glands in recurrent secondary hyperparathyroidism. World J Surg. (2015) 39(2):400–9. 10.1007/s00268-014-2797-3
34.
RandoneBCostiRScattonOFullaYBertagnaXSoubraneOet alThoracoscopic removal of mediastinal parathyroid glands: a critical appraisal of an emerging technique. Ann Surg. (2010) 251(4):717–21. 10.1097/SLA.0b013e3181c1cfb0
35.
PavlovicsSRadzinaMNiciporukaRRatnieceMMikelsoneMTauvenaEet alContrast-enhanced ultrasound qualitative and quantitative characteristics of parathyroid gland lesions. Medicina. (2021) 58(1):2. 10.3390/medicina58010002
36.
AchourICharfiSChaabouniMAChakrounAGuermaziFHammamiBet alParathyromatosis: an uncommon cause of recurrent hyperparathyroidism. Rev Med Interne. (2017) 38(1):61–4. 10.1016/j.revmed.2016.03.005
37.
TaiebDHindieEGrassettoGCollettiPMRubelloD. Parathyroid scintigraphy: when, how, and why? A concise systematic review. Clin Nucl Med. (2012) 37(6):568–74. 10.1097/RLU.0b013e318251e408
38.
LiCLvLWangHWangXYuBXuYet alTotal parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: systematic review and meta-analysis. Ren Fail. (2017) 39(1):678–87. 10.1080/0886022X.2017.1363779
39.
LiuMEQiuNCZhaSLDuZPWangYFWangQet alTo assess the effects of parathyroidectomy (TPTX versus TPTX+AT) for secondary hyperparathyroidism in chronic renal failure: a systematic review and meta-analysis. Int J Surg. (2017) 44:353–62. 10.1016/j.ijsu.2017.06.029
40.
HouJShanHZhangYDengXGuoBKangJet alNetwork meta-analysis of surgical treatment for secondary hyperparathyroidism. Am J Otolaryngol. (2020) 41(2):102370. 10.1016/j.amjoto.2019.102370
41.
LiJGXiaoZSHuXJLiYZhangXZhangSZet alTotal parathyroidectomy with forearm auto-transplantation improves the quality of life and reduces the recurrence of secondary hyperparathyroidism in chronic kidney disease patients. Medicine. (2017) 96(49):e9050. 10.1097/MD.0000000000009050
42.
LauWLObiYKalantar-ZadehK. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. (2018) 13(6):952–61. 10.2215/CJN.10390917
43.
YinLGuoDLiuJYanJ. The role of 99mTc-MIBI SPECT-CT in reoperation therapy of persistent hyperparathyroidism patients. Open Med. (2015) 10(1):462–7. 10.1515/med-2015-0064
44.
YuanLLKanYMaDQYangJG. Combined application of ultrasound and SPECT/CT has incremental value in detecting parathyroid tissue in SHPT patients. Diagn Interv Imaging. (2016) 97(2):219–25. 10.1016/j.diii.2015.08.007
45.
ZengMLiuWZhaXTangSLiuJYangGet al99mTc-MIBI SPECT/CT imaging had high sensitivity in accurate localization of parathyroids before parathyroidectomy for patients with secondary hyperparathyroidism. Ren Fail. (2019) 41(1):885–92. 10.1080/0886022X.2019.1662804
46.
ZhangRZhangZHuangPLiZHuRZhangJet alDiagnostic performance of ultrasonography, dual-phase 99mTc-MIBI scintigraphy, early and delayed 99mTc-MIBI SPECT/CT in preoperative parathyroid gland localization in secondary hyperparathyroidism. BMC Med Imaging. (2020) 20(1):91. 10.1186/s12880-020-00490-3
47.
LiXLiJLiYWangHYangJMouSet alThe role of preoperative ultrasound, contrast-enhanced ultrasound, and 99mTc-MIBI scanning with single-photon emission computed tomography/x-ray computed tomography localization in refractory secondary hyperparathyroidism. Clin Hemorheol Microcirc. (2020) 75(1):35–46. 10.3233/CH-190723
48.
JiangSQYangTZouQXuLYeTKangYQet alThe role of 99mTc-MIBI SPECT/CT in patients with secondary hyperparathyroidism: comparison with 99mTc-MIBI planar scintigraphy and ultrasonography. BMC Med Imaging. (2020) 20(1):115. 10.1186/s12880-020-00517-9
49.
HiramitsuTTominagaYOkadaMYamamotoTKobayashiT. A retrospective study of the impact of intraoperative intact parathyroid hormone monitoring during total parathyroidectomy for secondary hyperparathyroidism: STARD study. Medicine. (2015) 94(29):e1213. 10.1097/MD.0000000000001213
50.
ZhangLXingCShenCZengMYangGMaoHet alDiagnostic accuracy study of intraoperative and perioperative serum intact PTH level for successful parathyroidectomy in 501 secondary hyperparathyroidism patients. Sci Rep. (2016) 6:26841. 10.1038/srep26841
51.
ShanCXQiuNCZhaSLLiuMEWangQZhuPPet alA novel surgical strategy for secondary hyperparathyroidism: purge parathyroidectomy. Int J Surg. (2017) 43:112–8. 10.1016/j.ijsu.2017.05.062
Summary
Keywords
recurrence, parathyromatosis, supernumerary parathyroid glands, hyperparathyroidism, secondary, case reports
Citation
Li L, He C, Cheng G, Cao J, Wang C, Tang Y and Zhang W (2023) Recurrent renal secondary hyperparathyroidism caused by supernumerary mediastinal parathyroid gland and parathyromatosis: A case report. Front. Surg. 10:1135596. doi: 10.3389/fsurg.2023.1135596
Received
01 January 2023
Accepted
27 February 2023
Published
20 March 2023
Volume
10 - 2023
Edited by
Brian Bieber, Arbor Research Collaborative for Health, United States
Reviewed by
Ioannis Koutelidakis, Aristotle University of Thessaloniki, Greece Barış Saylam, Ankara City Hospital, Türkiye
Updates
Copyright
© 2023 Li, He, Cheng, Cao, Wang, Tang and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yufu Tang tangyufu0227@163.com Wei Zhang zhang_wei_1980@163.com
These authors have contributed equally to this work
Specialty Section: This article was submitted to Otorhinolaryngology—Head and Neck Surgery, a section of the journal Frontiers in Surgery
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.